Kontakt

Anfahrt

Über uns

Technologieangebote

Animal Models
Ascenion

Animal Models
MGC Foundation

	A Central Target in Neutrophil Granulopoiesis
	A method for inducing cellular apoptosis
	Acute Liver Failure
	Aß-directed Peptides
	Ansamitocin Analogues
	Argyrin – A promising novel anti-cancer compound
	Broad-spectrum antiviral peptides
	Metabolic Syndrome
	Biocompatible matrix
	CD3 Kappa Immune enhancing drug
	CD3 Kappa adjuvant
	CFHR-proteins – complement inhibitors
	DC Maturation Cocktail
	Dendritic cell modulation
	direct epitope/antigen identification
	EBV-VLP as vaccine
	Expression of immunoglobulin-cytokine fusion proteins
	GARP controlling Treg
	Hepatocytes
	Her2/neu-specific T cell receptors
	IL-6 /IL-8 Inhibitor
	Increasing Liver Regeneration
	Hairloss
	Immunomodulating Peptide
	Induced senescence against tumor genesis
	Lipoxygenase wound healing
	MALP-2 in Wound Healing
	MHC Loading Catalysis
	MicroRNA-221 – new treatment option for fulminant liver failure
	Myosin-Inhibitors
	Inhibition of EpCAM cleavage
	Nerve guidance conduit
	New Antidepressant Target
	New antimitotic Rhizoxin derivatives
	Novel Antimicrobial Peptides
	Novel Antimicrobial and Antiviral Peptides
	Novel therapeutic/diagnostic antibody to carbonic anhydrase XII
	Obesity-associated Diabetes
	T-cell therapies
	Peptide for improved pain management
	Primary Haemostasis
	Sepsis Therapy via NK cells
	Sepsis Treatment
	Antibiotic from Myxobacteria
	TAK1 - regenerative therapy
	TCR gene transfer for CLL
	Treatment of anxiety and depression
	Treatment of osteoporosis
	Treatment of EBV-associated diseases
	Treatment of sepsis with MALP-2
	Tumor Targeting

Tools

Vaccines

Veterinary Medicine

GARP controlling Treg

Reference Number TO 02-00190

The Challenge

A variety of diseases including e.g. cancer, transplant rejection and type I diabetes are associated with a dysfunction of the human immune system In such cases, the human immune system is suppressed or activated excessively. The modulation of the immune system remains a great challenge as most therapies cause a variety of side effects and new therapeutic approaches for improved immune modulation are highly desired to continuously advance patient care.

Simplified model of the positive GARP-FOXP3 feedback loop
(source Probst-Kepper)

Technology
The present technology discloses glycoprotein-A repetitions predominant (GARP) as a constituent of the genetic program of human regulatory CD4+CD25hi T (Treg) cells and confirms its FOXP3-regulating function in natural human Treg cells. GARP controls FOXP3 in human Treg cells and is able to convert antigen-specific helper T cells into regulatory T cells. Thereby GARP acts as a key receptor controlling FOXP3 in Treg cells following T cell activation in a positive feedback loop assisted by LGALS3 and LGMN, which represents a promising new approach for the therapeutic manipulation of T cells in human diseases. The technology opens up the possibility for the generation of antigen-specific regulatory T cells for clinical applications. It further could provide the basis to develop new strategies and tools to induce or inhibit Treg cells in chronic infection, tumor immunotherapy, autoimmune diseases and transplantation.

Commercial Opportunity
The technology is offered for co-development or in-licensing.

Patent situation
European patent application filed in 2006, international application published 2007 (WO 2007/113301), European and US patent application pending.

Further Reading
Probst-Kepper et al. J. Cell Mol Med. 2009. DOI: 10.1111/j.1582-4934.2009.00782.x

Download als PDF

Kontakt:

Sabina Heim, Ph.D.
Technology Manager
Ascenion GmbH

T: +49 (0)531-6181-2090
F: +49 (0)531-6181-2098
heim(at)ascenion.de

Impressum

Sitemap